Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) are standard treatments for advanced non-small cell lung cancer (NSCLC); however, evidence regarding their relative efficacy and safety is lacking. This study compared the efficacy and safety of all currently available ICI treatments in patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Liang, Xueyan, Li, Huijuan, Chen, Xiaoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Meta Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508436/
https://www.ncbi.nlm.nih.gov/pubmed/37596898
http://dx.doi.org/10.1097/CM9.0000000000002750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508436/
https://www.ncbi.nlm.nih.gov/pubmed/37596898
http://dx.doi.org/10.1097/CM9.0000000000002750

Ejemplares similares